B+
Bull case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
WVE
Wave Life SciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Supportive WVE-006 monthly-dose data could strengthen the planned AATD registrational path, while convincing WVE-007 Phase 2a differentiation could add obesity-program value. GSK's September candidate selection triggered a disclosed $12 million milestone, but further collaboration milestones remain contingent.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.9.
What can break
Clinical spending and future financing needs could change the June 30 cash-runway estimate; check the October 27 financial update. [#SEC-8K-2026-07-30] Wave results announcement
Momentum
4
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.90 · Bull $5.50 · Bear $1.40Analysis 2026-10-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $18.42
Why
Momentum4 · Δ7d +0.9
Value41 · Δ7d -0.0
Sentiment51 · Δ7d -2.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -2.9.
Contradictions & invalidation
- • Clinical spending and future financing needs could change the June 30 cash-runway estimate; check the October 27 financial update. [#SEC-8K-2026-07-30] Wave results announcement
- • Further GSK collaboration payments depend on future program progress; the September candidate-selection payment does not establish recurring revenue. Wave GSK update
- • A weak monthly-dose biomarker or safety profile, delayed trial execution, or limited WVE-007 benefit over established obesity treatments could undermine the asset case.
Catalyst clock
2026-10-27
Third-quarter cash and program update
Lead driver: Sentiment · See AI snapshot
Momentum
4
8% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
+1.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
51
45% active weight
Current posture
7d trendSoftening
Δ7d
-2.9
Δ21d
-42.1
Why this grade
Composite grade D. Momentum 4.2 / Value 40.6 / Sentiment 51.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.90
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$633.1M
Beta
-1.77
Shares Out
197.23M
P/E (TTM) · Derived
-2.6
P/S (TTM)
25.10
P/FCF (TTM) · Derived
-3.15
Rev YoY
-73.9%
EPS YoY
+10.5%
Gross Margin
+86.0%
Op Margin
-333.4%
Net Debt
-$584.3M
Current Ratio
9.99
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data